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Glutamate recognition by neurotransmitter receptors often
relies onArg residues in the binding site, leading to the assump-
tion that charge-charge interactions underlie ligand recogni-
tion. However, assessing the precise chemical contribution of
Arg side chains to protein function and pharmacology has
proven to be exceedingly difficult in such large and complex
proteins. Using the in vivo nonsense suppression approach, we
report the first successful incorporation of the isosteric, titrata-
ble Arg analog, canavanine, into a neurotransmitter receptor in
a living cell, utilizing a glutamate-gated chloride channel from
the nematodeHaemonchus contortus. Our data unveil a surpris-
ingly small contribution of charge at a conserved arginine side
chain previously suggested to form a salt bridge with the ligand,
glutamate. Instead, our data show that Arg contributes crucially
to ligand sensitivity via a hydrogen bond network, where Arg
interacts both with agonist and with a conserved Thr side chain
within the receptor. Together, the data provide a new explana-
tion for the reliance of neurotransmitter receptors on Arg side
chains and highlight the exceptional capacity of unnatural
amino acid incorporation for increasing our understanding of
ligand recognition.
Neurotransmitter receptors are vital signaling proteins that
are embedded in the cell membrane and trigger intracellular
changes in response to extracellular chemical signals. The two
classical receptor types are metabotropic, G-protein-coupled
receptors (GPCRs) that act over seconds or minutes via intra-
cellular second messengers (1), and ionotropic, ligand-gated
ion channels (LGICs)2 that mediate ion flux across the mem-
brane on the millisecond timescale (2). The rapid chemo-elec-
tric signaling of LGICs is perfectly suited to the nervous system,
where activation of sodium channels and chloride channels
mediates excitatory and inhibitory signals, respectively (2). The
first step in the process of activation is the recognition of a
specific ligand, which in the case of the animal nervous system
is very often the neurotransmitter glutamate (3).
Glutamate binding to neurotransmitter receptors has been
studied in great detail, reflected in X-ray structures of ligand-
receptor complexes of both LGICs (4, 5) and GPCRs (6). Per-
haps not surprisingly, each complex contains an Arg side chain
in close proximity to at least one of the glutamate carboxylates,
suggestive of ionic interactions betweennegatively charged car-
boxylate and positively charged guanidino groups. Reduced
function upon Ala substitution confirms the importance of
these Arg residues in glutamate recognition in each receptor
subfamily (7–9), but despite this apparent functional evidence
for a charge-charge interaction, replacing a large Arg side chain
with a much smaller Ala side chain involves more physico-
chemical changes than merely removing a positive charge. As
such, the precise contribution of highly conserved Arg side
chains in ligand recognition remains unknown.
Here, we have sought experimental evidence for charge-
charge interactions in ligand recognition, focusing on theAVR-
14B glutamate-gated chloride channel (GluCl (10)). GluCls are
invertebrate-specific members of the pentameric ligand-gated
ion channel (pLGIC or “Cys-loop receptor”) family, sharing sig-
nificant homology with vertebrate GABA and acetylcholine
receptors and constituting an important antiparasitic drug tar-
get (11). Despite the fact that a Caenorhabditis elegans GluCl
was the first eukaryotic pLGIC to be visualized by X-ray crys-
tallography (5), themolecular basis for neurotransmitter recog-
nition in GluCls has received little experimental interrogation,
as compared with vertebrate homologs. It has recently been
shown, however, that inGluCls, glutamate recognition involves
interactions between aromatic residues on the principal face of
the binding site with the glutamate amine (7), as well as inter-
actions between Arg residues in the binding site with the glu-
tamate carboxylate groups (12), as illustrated in supplemental
Fig. S1. We replaced Arg76 in the glutamate binding site with a
titratable amino acid, providing us with the unprecedented
opportunity to test glutamate sensitivity when an isosteric side
chain is present but charged or uncharged. The results indicate
only a small role of positive charge and unveil another unique
property of Arg side chains that contributes to glutamate sen-
sitivity, namely the ability to form hydrogen bonds both with
the agonist and with vicinal receptor side chains.
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Results
To test whether positive charge of Arg residues 76 and 95 is
sufficient for glutamate recognition in the glutamate binding
site of the AVR-14B GluCl, we replaced these individually with
Lys via site-directed mutagenesis and measured glutamate-
gated chloride currents with two electrode voltage clamp
experiments (Fig. 1, A and B). Given the water-accessible loca-
tion of these positions in GluCls (13) and the positive charge on
Lys side chains in such environments (14), one would expect
glutamate sensitivity of mutant receptors to reflect that of WT
receptors if positive charge were themain contribution of these
side chains. However, we observed that glutamate sensitivity
was practically abolished at R76K and R95K mutants (Fig. 1B),
suggesting that positive charge alone at these positions is not
sufficient for high glutamate sensitivity.
Although Arg-to-Lys substitution largely retains side chain
size and charge, it also involves the loss of two potentially
hydrogen-bonding (H-bonding) nitrogen atoms (Fig. 2A),
which could also underlie the loss of glutamate sensitivity we
observed in R76K and R95K mutants. Assessing the precise con-
tributions of charge or H-bonding of the Arg side chain to gluta-
mate recognition would thus require substitution with an
uncharged but otherwise isosteric analog. To this end, we sought
to replace Arg76 or Arg95 with canavanine (Can), an isosteric Arg
analogwith a pKaof 7 (15) (Fig. 2A), reasoning that experiments at
low and high pH would assay glutamate sensitivity when a single
guanidino side chain is protonated or deprotonated, respectively.
Site-specific incorporationofCanwas achievedby the in vivonon-
sense suppressionmethod (16) (Fig. 2B). Successful incorporation
of Can at position Arg76 was evident in robust glutamate-gated
currents through Can76, receptors, but although currents were
also observed for Can95, these were not significantly greater than
controls lackingCan (Fig. 2C; 18 5 nA,n 10; 4 2 nA,n 8).
This made further characterization of Can95 receptors difficult,
and we chose not to investigate these further.
When we measured glutamate sensitivity of Can76 receptors
at pH 7.0, at which one would expect only50% of Can76 side
chains to be protonated, wewere surprised to find that the EC50
for activation by glutamate was 48 7M (n 6), and thus not
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FIGURE 1. Arg-Lys substitutions drastically reduce glutamate recogni-
tion. A, X-ray structure of GLC-1 GluCl (PDB 3RIF; gray shading, notional cell
membrane). Magnified view shows glutamate binding site and selected
amino acid side chains. These include GLC-1 arginine residues 37 and 56,
which are labeled Arg76 and Arg95 to describe the equivalent residues from
the AVR-14B GluCl used in the present study. B, left, example recordings of
glutamate (Glu) and ivermectin (IVM, 1 M) responses at oocytes expressing
mutant AVR-14B GluCls (scale bars: x, 5 s; y, 2 A). Activation by IVM, which
binds elsewhere on the receptor, confirms cell surface expression in the
absence of Glu-gated currents. Right, mean  S.E. (n  4–8) peak current
responses to increasing concentrations of Glu, normalized to maximum Glu-
gated current (WT) or maximum IVM-gated current (mutants).
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FIGURE 2. Incorporation of titratable arginine analog, canavanine. A, L-ly-
sine (Lys), L-arginine (Arg), and L-canavanine (Can). B, graphic illustrating non-
sense suppression of Arg76UAG mRNA by co-injection of Can-ligated tRNA
into Xenopus laevis oocytes (yellow/brown spheres). C, mean peak current
amplitude ( S.E.) in response to 10 mM glutamate at oocytes injected with
mRNA and tRNA  Can (n  8–15; *, p  0.05; n.s. not significant, ANOVA).
Inset shows example responses to 10 mM glutamate at oocytes (pH  7)
injectedwith indicatedRNAcombinations (scale bars: x, 5 s; y, 20 nA).D, exam-
ple recordings of current responses to increasing concentrations of gluta-
mate and mean S.E. peak current responses (n 5–8; normalized to max-
imum glutamate-gated current) at Can76 GluCls (Can76). Scale bars: x, 10 s; y,
100 nA. E, left, glutamate-gated currents at oocytes expressing wild-type or
Can76 GluCls continuously perfused at pH 7.0 or 5.8, as indicated (scale bars: x,
30 s; y, 100nA).Right,meanS.E. peak current responses to30Mglutamate,
normalized tomaximumglutamate-gated current (I30 M/Imax; n 5–8; *, p
0.05, ***, p 0.001, Student’s t test).Gray arrows illustrate inhibition of 30M
glutamate-gated current. Can76 pH 7.0 recording in E is repeated from D.
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significantly different fromWT receptors (41 11 M, n 8).
At pH 8.5, when even fewer, if any, Can76 side chains are
expected to be protonated, we observed only amodest decrease
in glutamate sensitivity (Fig. 2D), with the EC50 significantly
increased to 119 11M (Table 1). A further increase in pH to
9.2 saw no additional rise in EC50 value (Fig. 2D; Table 1), sug-
gesting that the effect was saturated around pH 8.5. No such
pH-dependent shift was seen for WT receptors (Table 1), in
whichArg76 residues are always protonated. This indicates that
a 2-fold decrease in glutamate sensitivity in conditions that
deprotonate the Can (not Arg) side chains is specific for recep-
tors incorporating a Can residue in the glutamate binding site.
Unfortunately, we could not measure the effects of fully proto-
nated Can76 side chains, as acidic pH causes significant inhibi-
tion of function even inWT receptors (Fig. 2E), as is the case in
structurally related GABA and glycine receptors (17, 18). To
verify the 2-fold decrease in glutamate sensitivity observedwith
an uncharged analog at position 76, we attempted to replace
Arg76 with citrulline, an analog in which one  nitrogen is
replaced by an oxygen and which is uncharged (19), via non-
sense suppression, but this was not successful (data not shown).
Thus, and although a complete titration could not be completed,
ourdata showthat in conditions inwhich theoretically only 50%of
Can76 side chains carry a positive charge, Can76 receptors show
very similar glutamate sensitivity toWTArg76 receptors (Table 1).
Perhaps more strikingly, upon deprotonation and loss of positive
charge in Can76 receptors, a mere 2-fold reduction in glutamate
sensitivity is observed. This is a modest reduction in agonist sen-
sitivity as compared with the 10,000-fold reduction caused by
R76N or even R76K mutations in this very receptor (12) (Fig. 1),
raising the possibility that a more substantial contribution to glu-
tamate binding derives from someproperty of theArg (or, indeed,
Can) side chain other than positive charge.
Although some of that contribution is presumably via
H-bonds between Arg (or Can) NH2 group(s) and glutamate
(Fig. 3A), we considered that the Arg NH group could also be
important. Indeed, we noticed in the GLC-1 GluCl-glutamate
X-ray structure (Protein Data Bank (PDB) 3RIF (5)) that
although not in direct contact with the bound agonist, the
hydroxyl oxygen atom of a Thr residue (equivalent to Thr93 in
the AVR-14B GluCl) is located in close (2.9 Å) proximity to the
NH of the Arg equivalent to Arg76 (Fig. 3A). If this potential
H-bond were important for glutamate sensitivity, we reasoned
that the T93S substitution should retain glutamate sensitivity,
as Ser also possesses a -hydroxyl group. In contrast, Val is
sterically similar to Thr but devoid of the hydroxyl, andmutant
T93V receptors would be expected to show decreased gluta-
mate sensitivity. Indeed, when we measured glutamate-gated
currents at these mutants, T93V receptors showed drastically
reduced glutamate sensitivity, barely responding to millimolar
concentrations (Fig. 3, B and C). By contrast, T93S receptors
showed a 370-fold increase in glutamate sensitivity as com-
pared with WT (Fig. 3, B and C; Table 2), confirming that the
hydroxyl at this position is required for regular (or increased)
glutamate sensitivity, likely through an interaction with Arg76.
Seeking specific evidence for this interaction, we performed
double mutant cycle analysis, according to which the T93S
mutation should not restore high glutamate sensitivity onR76K
mutant receptors because these WT residues are coupled and
the effects of their mutation are not simply additive (20–22). In
contrast, the combined effects of mutating independent resi-
dues are additive, and the T93S mutation might be expected to
confer higher glutamate sensitivity on R95K receptors, as we do
not expect coupling between these two residues. Indeed, double
mutant T93S/R95K receptors responded to glutamate in a con-
centration range between T93S and R95K single mutants (Fig.
TABLE 1
Glutamate sensitivity of Can76 and Arg76 GluCls
For comparisonwithCan76 (oocytes injectedwith 40 ng ofUAGmutantmRNAand
tRNA-Can; Fig. 2), oocytes were injected with only 0.04 ng of Arg76 WTmRNA, to
keep WT expression levels low, and Imax values comparable with Can76. ***, p 
0.001 as compared with pH 7.0 (ANOVA with Tukey’s post test).
EC50a Imax n
M nA
Can76
pH 7.0 48 7 60 40 6
pH 8.5 119 11*** 214 91 5
pH 9.2 118 17*** 110 27 6
Arg76 (WT)
pH 7.0 41 11 241 51 8
pH 8.5 43 5 170 47 8
pH 9.2 57 7 428 91 7
a EC50 value was calculated by plotting current amplitude against glutamate con-
centration and fitting with Hill equation for experiments at individual oocytes
and then averaged. Data are mean S.E.
FIGURE 3. Conventional mutagenesis shows the importance of Thr93 in
glutamate recognition.A,magnifiedviewofGLC-1 crystal structure illustrat-
ing proximity of Thr93 hydroxyl oxygen to Arg76  nitrogen (2.9 Å; orange
dashed line; numbers refer to equivalent residues in AVR-14B). Dashed lines
indicate inter-atomic distances 3.5 Å. Amino acid sequence alignment
shows selected Loop G and Loop D residues from ecdysozoan GluCls (dark
font), lophotrochozoan GluCls and vertebrate and invertebrate GABA and
glycine receptors (light font). B, example recordings of glutamate (Glu) and
ivermectin (IVM) responses at oocytes expressing mutant AVR-14B GluCls
(scale bars: x, 5 s; y, 2A). C, mean S.E. (n 6–8) peak current responses to
increasing concentrations of glutamate, normalized tomaximumglutamate-
gated current (WT and T93S) or maximum IVM-gated current (T93V).
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4A; Table 2), indicative of independence. R76K/T93S receptors,
however, showed no greater glutamate sensitivity than single
mutant R76K receptors (Fig. 4A), and analysis indicated an
energetic coupling of 14 kJ/mol between Arg76 and Thr93
(Fig. 4B), which we interpret as evidence for a strong H-bond
between the Arg NH and Thr OH groups.
Discussion
Taken together, these results suggest that the positive charge
of Arg76 contributes little to glutamate binding in GluCls.
Instead, our results show that two other aspects of the Arg side
chain contribute to effective glutamate recognition. First, the
data suggest that H-bonds between the Arg NH2 group(s) and
the agonist -carboxylate are important, as conventional Asn
and Lys mutations that remove this moiety of Arg are severely
detrimental to glutamate recognition, whereas the non-canon-
ical substitution of Can, which retains NH2 groups, retains
WT-like glutamate sensitivity. Second, the NH of Arg appears
to interact closely with a vicinal receptor hydroxyl side chain,
the removal of which via Val substitution drastically reduces
glutamate sensitivity. Based on available GluCl structures, this
interaction is likely to stabilize Arg for its interaction(s) with
the glutamate -carboxylate (Fig. 3A). Notably, this Loop D
hydroxyl side chain is highly conserved in GluCls that possess
the Loop G Arg (Arg76 in AVR-14B), which interacts with the
glutamate -carboxylate. By contrast, the Loop D hydroxyl is
absent in GluCls where instead a Loop A Arg (on the opposing
face of the binding site, equivalent to Q141 in AVR-14B) inter-
acts with the glutamate -carboxylate (Fig. 3A) (12).
Conventional mutagenesis is an indispensable tool for dis-
section of protein structure and function, but in fine-tuning the
details of ligand recognition, it is limited by the numerous
physico-chemical changes involved in most substitutions (23).
This is perhaps especially the case for Arg, where conventional
analogs Lys andHis are noticeably smaller andmore frequently
than Arg uncharged in physiological settings (14, 24). Previous
attempts to circumvent the limitations of conventional
mutagenesis by incorporating unnatural Arg analogs have been
few (19, 25, 26) and arguably difficult (27). Our use of the in vivo
nonsense suppressionmethodwas successful for one of the two
positions tested, and despite limited efficiency (currents
through Can76 were substantially smaller than conventional
mutant receptors; compare Imax in Tables 1 and 2), the data
strongly support the notion of robust and specific Can incorpo-
ration in three ways. First, the level of nonspecific incorpora-
tion of endogenous amino acids, as inferred from the very low
current levels upon co-injection of uncharged tRNA, was very
low (Fig. 2C). Second, although all conventional replacements
at position 76 tested here and elsewhere (7, 12) resulted in dras-
tic losses in glutamate sensitivity, we found Can incorporation
to yield WT-like glutamate sensitivity (at pH 7.0; Table 1).
Lastly, and perhaps most significantly, we found the agonist
sensitivity of Can76 receptors to be titratable between pH 7.0
and 8.5, a property that would be highly unlikely in the event of
endogenous amino acids incorporating into this position. We
note here that in our hands the incorporation of Can was more
successful than citrulline at positions 76 and 95. However, we
cannot assess with certainty the reason for this difference,
which could be due to ribosomal recognition of the charged
tRNA, protein folding, or protein function.
In conclusion, Can incorporation, together with subsequent
conventional mutagenesis, has unveiled crucial determinants
of ligand recognition that had previously escaped identifica-
tion. Our results suggest that the common occurrence of Arg
residues in glutamate binding sites is related to the ability ofArg
side chains to participate in H-bonds both with ligand and with
vicinal receptor side chains simultaneously. Thus, the unique
propensity of Arg for forming multiple H-bonds, as described
previously in the context of intramolecular interactions in
other protein families (28), seems to have been utilized by Glu-
TABLE 2
Glutamate sensitivity of WT and conventional mutants
Oocytes were injected with 10 ng of WT or mutant mRNA. ***, p  0.001 as
compared with WT (ANOVA with Tukey’s post test).
EC50a Imaxb n
M A
WT 17 3 5.0 0.5 4
R76K 100 mMc 0.10 0.02 8
T93S 0.046 0.011*** 4.8 0.7 6
R95K 100 mMc 0.05 0.01 7
R76K/T93S 100 mMc 0.44 0.09 8
R95K/T93S 530 140 1.3 0.4 9
a EC50 value was calculated by plotting current amplitude against glutamate con-
centration and fitting with Hill equation for experiments at individual oocytes
and then averaged. Data are mean S.E.
bMaximum glutamate-gated peak currents. Mean S.E.
c For certain mutants, saturation in the concentration-response relationship was
not reached, up to 30 mM glutamate. EC50 values are therefore estimated to be
well over 100 mM.
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FIGURE 4. Double mutant cycle analysis. A, glutamate-gated currents at
oocytes expressing double mutant T93S/R95K or R76K/T93S receptors and
mean ( S.E.) data. Robust activation by IVM indicates successful expression
of R76K/T93S despite small responses to glutamate. WT and single mutant
data are repeated from earlier figures for comparison. B, principles of double
mutant cycle analysis and analysis of Arg76–Thr93 and Arg95–Thr93 coupling.
For two residues “A” and “B,” EC50 values ofWT (AB), singlemutant AB, single
mutant AB, and doublemutant AB are used to calculate the coupling coef-
ficient,, from which the coupling energy, 		G, can be calculated (22). Our
final values for  and 		G are only estimates because the EC50 values of
certain single and double mutants could not be calculated: here the EC50
values have been estimated from A.
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Cls for the specific functional requirements of ligand recogni-
tion. The results also complement work on tetrameric iono-
tropic glutamate receptors (iGluRs), regarding both the unique
role of Arg and the occurrence of vicinal hydroxyl side chains
that could stabilize binding site architecture. In NMDA-type
iGluRs, for example, Lys substitution of the Arg residue that
binds the ligand -carboxylate abolishes glutamate sensitivity
(29, 30), much like R76K and R95K substitutions in the GluCl.
Remarkably, NMDA-type iGluRs also contain Ser and Thr res-
idues, whose side chain hydroxyl oxygens are, similar to Thr93
in the GluCl, as close as 2.7 Å to other side chains that form the
glutamate binding site (29, 31), and whose substitution for Ala
drastically reduces glutamate sensitivity (29).
We present here, to our knowledge, the first example of Arg
analog incorporation into membrane-bound receptors, and as
such, these results describe an incisive approach to dissecting
chemical interactions in a broad and therapeutically relevant
family of membrane proteins. Interestingly, an H-bond net-
work adjacent to the ligand binding site has been proposed for
the structurally related glycine receptor (32), suggesting that
stabilization of ligand binding by such H-bond networks could
be a conserved feature of ligand recognition by pLGICs.
Experimental Procedures
Chemical Synthesis—All reagents were of analytical grade
and were used directly as received. The reagents were pur-
chased fromSigma-Aldrich, unless statedotherwise. LC-MSanal-
yses of synthesized compounds were performed on a Waters
ACQUITY ultra high performance liquid chromatography sys-
tem. Eluents A (0.1% HCOOH in water (v/v)) and B (0.1%
HCOOHin acetonitrile (v/v))were used in a linear gradient (100%
A to 95% B) in a run time of 2.5 at a flow rate of 0.6 ml/min.
Nvoc-Can(Nvoc)-OH—Nvoc-Can(Nvoc)-OH was synthe-
sized according to the procedure used elsewhere (33). L-Cana-
vanine (L--amino--(guanidinooxy)-n-butyric acid, 50 mg of
H-Can-OH) was suspended in 1,4-dioxane (5 ml) along with
sodium bicarbonate (120 mg, 5 eq). The resulting mixture was
cooled down on ice bath, and NVOC-Cl (4,5-dimethoxy-2-ni-
trobenzyl chloroformate, 175mg, 2,2 eq) was added in one por-
tion. The reaction mixture was left stirring overnight. Water (5
ml) was added, the resulting mixture was extracted with ethyl
acetate (3 
 10 ml), and the organic layer was discarded. The
water layer was acidified with 1 M HCl to pH 4, and then the
compound was extracted with ethyl acetate (3 
 20 ml), and
the combined organic layer was dried over sodium sulfate and
concentrated in vacuo. The resulting yellow oil (32 mg) was
used directly in the next step. ESI MS calculated for C25
H31N6O15 (MH) 655.18; found 655.2.
Nvoc-Can(Nvoc)-OCH2CN—The compound from the previ-
ous step was dissolved in 1 ml of chloroacetonitrile, and trieth-
ylamine (145l, 1mmol)was added. The reactionwas stirred at
room temperature overnight. Chloroacetonitrile was then
removed in vacuo, and residual oil was dissolved in ethyl acetate
(2 ml) and triturated with glass pipette. Precipitate of triethyl-
amine hydrochloride was filtered off and washed with an addi-
tional portion of ethyl acetate (5 ml). Combined filtrate was
concentrated under reduced pressure and dried overnight in
vacuo. Obtained cyanomethyl ester (white to yellow solid, 36
mg) was used without further purification. ESI MS calculated
for C27H32N7O15 (MH) 694.20; found 694.1.
Nvoc-Can(Nvoc)-OpdCpA—pdCpA (5-O-phosphoryl-2-
deoxycytidylyl-(335)adenosine (GE Healthcare/Dharma-
con, 10 mg) was suspended in 200 l of dry N,N-dimethylfor-
mamide, and Nvoc-Can(Nvoc)-OCH2CN (20 mg) and then
NBu4OAc (10 mg) were added. The reaction was shaken at
37 °C until pdCpAwas fully dissolved. Another portion (10mg)
of pdCpAwas added, and the reaction was shaken at 37 °C until
pdCpAwas almost fully reacted (ultra performance liquid chro-
matography MS). 1 ml of ice-cold ether was added to the reac-
tion mixture, and precipitate was collected by centrifugation.
The residue was dissolved in 100 l of acetonitrile and precip-
itated with additional 1 ml of ice-cold ether. White-to-yellow
residue was dried in an N2 stream. The compound was purified
by preparative reverse-phase HPLC on a C18 Phenomenex
Luna column (250
 20 mm, 5 m, 100 Å) on an Agilent 1260
LC system equipped with a diode array UV detector and an
evaporative light scattering detector. Eluents A (0.1% TFA in
H2O (v/v)) and B (0.1% TFA in MeCN (v/v)) were used in a
linear gradient (100% A to 100% B) in a run time of 20 min and
with a flow rate of 20 ml/min. Fractions, containing UV signa-
tures for both NVOC group and pdCpA, were collected, ace-
tonitrile was removed in vacuo, and the resulting water solu-
tion was lyophilized. The obtained residue (2.6 mg) was
dissolved in DMSO (100 l), and the final concentration was
adjusted to 3 mM by adding an additional volume of DMSO.
ESI MS calculated for C44H51N14O26P2 (M-H2OH)
1253.26, C44H50N14O26P2Na (M-H2ONa) 1275.24,
found 1253.3, 1275.3.
Expression of GluCls—All reagents were from Sigma-Al-
drich, unless otherwise stated. The cDNA of the AVR-14B
GluCl from Haemonchus contortus in the pT7TS vector (10)
was used for site-directed mutagenesis with custom-designed
primers (EurofinsGenomics) andPCRwith PfuUltra II FusionHS
DNA Polymerase (Agilent Technologies). cDNA was linearized
with XbaI (New England Biolabs), and mRNAs were synthesized
with the AmbionmMESSAGEmMACHINET7 transcription kit
(Thermo Fisher Scientific) and purified in RNeasy columns (Qia-
gen). For incorporation ofCan,we used the nonsense suppression
method, where aminoacylated Tetrahymena thermophila tRNA
(34) recognizing the amber stop codon UAG is co-injected into
Xenopus laevis oocytes along with receptor mRNA containing a
UAGmutation at the codon of interest (16), as follows. tRNAwas
prepared by ligation of full-length 5 and 3 DNA strands (Inte-
grated DNA Technologies), RNA synthesis with T7-Scribe tran-
scription kit (Cellscript), and purification with Chroma Spin
DEPC-H20 columns (Clontech). Aminoacylation of tRNA with
Nvoc-Can(Nvoc)-OpdCpAwasperformed in vitrousingT4DNA
ligase (New England Biolabs), and aminoacyl-tRNA was purified
with phenol-chloroform extraction and ethanol precipitation, air-
dried, and stored at80 °Cuntil use. Immediately before injection
into oocytes, aminoacyl-tRNA was resuspended in 1 l of water,
and NVOC was removed by 50-s exposure to UV light (400-watt
xenon lamp, Newport).
Oocytes fromXenopus laevis frogs (anesthetized in 0.3% tric-
aine, according to license 2014-15-0201-00031, approved by
the Danish Veterinary and Food Administration) were sepa-
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rated with forceps and then treated with 0.5 mg/ml Type I col-
lagenase (Worthington Biochemical) in OR2 (in mM, 2.5 NaCl,
2 KCl, 1 MgCl2, 5 HEPES, pH 7.4 with NaOH) with continuous
shaking at 200 rpm and 37 °C. These were incubated in OR2 at
18 °C until injection of mRNA. For conventional mutants and
WT mRNAs, 10 ng, in a volume of 40 nl (diluted in water), was
injected using a Nanoliter 2010 injector (World Precision Instru-
ments). For Can incorporation, 40 ng of UAG-mutant mRNA
together with aminoacyl tRNA, in a volume of 40 nl, was injected.
For lowerexpressionofWT(Table1), 0.04ngmRNAwas injected.
Oocytes were incubated in Leibovitz’s L-15 medium (Life Tech-
nologies) with 3 mM L-glutamine, 2.5 mg/ml gentamycin, 15 mM
HEPES (pH 7.4 with NaOH) until experiments.
Electrophysiological Recordings and Data Analysis—One day
after mRNA injection, oocytes were placed one at a time in a
custom-built chamber (35), perfusedwith bath solution (inmM,
96NaCl, 2KCl, 1.8 BaCl2, and either 5mMHEPES to pH7.0, 7.4,
8.5, or 9.2withNaOH/HCl or 5mMMES to pH5.8withNaOH/
HCl) for two-electrode voltage clamp experiments. L-Gluta-
mate (dissolved in bath solution) was applied for5 s with 1min
between subsequent applications using a ValveBank 8 perfusion
system (AutoMate Scientific). Ivermectin was applied for longer
until saturating current response was observed. Oocytes were
clamped at60mV, and currents were recorded withmicroelec-
trodes filled with 3 M KCl, OC-725C amplifier (Warner Instru-
ments), and Digidata 1550 digitizer (Molecular Devices) at 1 kHz
with 200-Hz filtering. Peak current responses to L-glutamate were
later analyzed in Clampfit 10 (Molecular Devices) with 10-Hz fil-
tering for illustration. Peak current responses were plot against
glutamate concentration using the four-parameter Hill equation
in Prism 6 (GraphPad), and parameters were compared statisti-
cally (tests described in Table 1) using Prism 6.
Amino Acid Sequence Alignment—Amino acid sequences
were retrieved from UniProt. Brief names (as in Fig. 3A), full
names, and UniProt sequence IDs (in parentheses) are as fol-
lows: GABAAR, human GABAAR 1 subunit (P14867); RDL,
Drosophila melanogaster RDL GABA receptor (P25123); GlyR,
human glycine receptor 1 subunit (P23415); GluCl-A,Aplysia
californica GluCl-2 (C7DLK0); GluCl-S, Schistosoma mansoni
GluCl-2.1 (T2C5A6); GluCl-D, D.melanogaster GluCl (Q94900);
GLC-2, C. elegans GluCl  (Q17328); GLC-1, C. elegans GluCl
 (G5EBR3); and AVR14B, H. contortus AVR-14B GluCl
(O46124). Sequences were aligned in MUSCLE (36) using
default parameters in the European Bioinformatics Institute
portal. For display in Fig. 3A, only three LoopG residues (AVR-
14B/O46124 residues 75–77) and five Loop D residues (AVR-
14B/O46124 residues 92–96) were shown.
Author Contributions—All authors conceptualized the design and
developed the methodology. T. L. and V. V. K. performed investiga-
tions. T. L. wrote the original draft, and all authors reviewed and edited
the manuscript; T. L. performed visualization. T. L. and S. A. P. were
responsible for funding acquisition; S. A. P. supervised the study.
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